Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis

Journal of Rheumatology

Volumn 30, Issue 6, 2003, Pages 1280-1290

  Matsuo, Atsushi ^b   Shuto, Toshihide ^a   Hirata, Go ^b   Satoh, Hideshi ^b   Matsumoto, Yoshihiro ^b   Zhao, Hongpu ^b   Iwamoto, Yukihide ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

Adjuvant Induced Arthritis; Bisphosphonates; Bone Destruction; Cartilage Destruction; Incadronate (YM175); Inflammation

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; INCADRONIC ACID; SODIUM CHLORIDE;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; CARTILAGE; CELL MIGRATION; CHEMOTAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MACROPHAGE; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; CALCANEUS; CARTILAGE; DIPHOSPHONATES; FEMALE; HINDLIMB; MALE; RATS; RATS, INBRED LEW; TARSAL BONES; TIBIA;

EID: 0038657557     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rodan GA, Fleisch HA. Bisphosphonate: mechanism of action. J Clin Invest 1996;97:2692-6.
2. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 1987;295:1301-5.
3. Thiebaud D, Jaeger P, Gobelet C, Jacquet AF, Burckhardt P. A single infusion of the bisphosphonate AHPrBP (APD) as treatment of Paget's disease of bone. Am J Med 1988;85:207-12.
4. Body JJ. Bone metastases and tumor-induced hypercalcemia. Curr Opin Oncol 1992;4:624-31.
5. Body JJ. Current and future directions in medical therapy: hypercalcemia. Cancer 2000;88 Suppl 12:3054-8.
6. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
7. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Breedveld FC. Clinical and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis: a double blind placebo controlled study. J Rheumatol 1994;21:2016-20.
8. Cantatore FP, Acquista CA, Pipitone V. Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 1999;26:2318-23.
9. Barbier A, Breliere JC, Remandet B, Roncucci R. Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate. Ann Rheum Dis 1986;45:67-74.
10. Flora L. Comparative antiinflammatory and bone protective effects of two bisphosphonates on rat adjuvant arthritis. Arthritis Rheum 1979;22:340-6.
11. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established adjuvant arthritis. Rheumatol Int 1994;14:139-47.
12. Zhao H, Shuto T, Hirata G, Iwamoto Y. Aminobisphosphonate (YM175) inhibits bone destruction in rat adjuvant arthritis. J Orthop Sci 2000;5:397-403.
13. Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J Rheumatol 1999;26:1972-82.
14. Dunn CJ, Galinet LA, Wu H, et al. Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates. J Pharmacol Exp Ther 1993;226:1691-8.
15. Kinne RW, Schmidt-Weber CB, Hoppe R, et al. Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes. Arthritis Rheum 1995;38:1777-90.
16. Graf J, Iwamoto Y, Sasaki M, et al. Identification of an amino acid sequence in laminin mediating cell attachment, chemotaxis, and receptor binding. Cell 1987;48:989-96.
17. Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S, Iwamoto Y. Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res 2001;92:429-38.
18. Harimaya K, Tanaka K, Matsumoto Y, Sato H, Matsuda S, Iwamoto Y. Antioxidants inhibit TNF-a induced motility and invasion of human osteosarcoma cells: possible involvement of NF κB activation. Clin Exp Metastasis 2000;18:121-9.
19. Crouch SP, Kozlowski R, Slater KJ, Fletcher J. The use of ATP bioluminescence as a measure of cell proliferation and cytotoxity. J Immunol Methods 1993;160:81-8.
20. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001;28:524-31.
21. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:613-20.
22. Pennanen N, Lapinjoki S, Urtti A, Monkkonen J. Effect of liposomal and free bisphosphonate on the IL-1β, IL-6 and TNF-α secretion from RAW 264 cells in vitro. Pharm Res 1995;12:916-22.
23. Rogers MJ, Chilton KM, Coxon FP, et al. Bisphosphonate induced apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 1996;11:1482-91.
24. Luckman SP, Coxon FP, Ebetino FH, Russell RG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophage. J Bone Miner Res 1998;13:1668-78.
25. Stevenson PH, Stevenson JR. Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986;38:227-33.
26. Gallacher SJ, Ralston SH, Patel U, Boyle IT. Side-effects of pamidronate. Lancet 1989;2:42-3.
27. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-62.
28. Adami A, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
29. O'Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA. Treatment of malignant hypercalcemia with aminohexane bisphosphonate (neridronate). Br J Cancer 1994;69:914-7.
30. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42:919-44.
31. Hughes DE, Mian M, Guilland-Cumming DF, Russell RG. The cellular mechanism of action of bisphosphonates. Drugs Exp Clin Res 1991;17:109-14.
32. Francis MD, Hovancik K, Boyce RW. NE-58095: a diphosphonate which prevents bone erosion and preserves joint architecture in experimental arthritis. Int J Tissue React 1989;11:239-52.
33. Osterman T, Kippo K, Lauren L, Hannuniemi R, Sellman R. Effect of clodronate on established collagen-induced arthritis in rats. Inflamm Res 1995;44:258-63.
34. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
35. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
36. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10.
37. Inoue I, Goto S, Mizotani K, et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNa levels for interleukin-1 beta, interleukin-6, cyclooxygenase-2 and p22phox by regulation of peroxisome prolixferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 2000;67:863-76.
38. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F. Simvastatin inhibits the monocyte expression of proinflammatory cytokine in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-31.
39. Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 1999;14:2048-56.
40. Konttinen YT, Salo T, Hanemaaijer R, et al. Collagenase-3 (MMP-13) and its activators in rheumatoid arthritis: localization in the pannus-hard tissue junction and inhibition by alendronate. Matrix Biol 1999;18:401-12.
41. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone 2001;28:461-4.
42. Saklatvala J. Tumor necrosis factor a stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986;322:547-9.
43. Ikebe T, Hirata M, Koga T. Human recombinant interleukin-1 mediated suppression of glycosaminoglycan synthesis in cultured rat costal chondrocytes. Biochem Biophys Res Commun 1986;140:386-91.
44. Ikebe T, Hirata M, Koga T. Effect of human recombinant tumor necrosis factor-a and interleukin 1 on the synthesis of glycosaminoglycan and DNA in cultured rat costal chondrocytes. J Immunol 1988;140:827-31.